Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Article Infectious Diseases

Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience

Arta Karruli et al.

Summary: Cefiderocol demonstrated efficacy and tolerability in treating highly co-morbid patients with multiresistant infections, making it a potential option for colistin-resistant pathogens or in cases at risk of kidney dysfunction.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades

Daniele Roberto Giacobbe et al.

Summary: Antimicrobial resistance, particularly carbapenem resistance in Gram-negative bacteria, poses a significant global health threat. The emergence of carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) has presented clinicians with unique challenges in managing severe infections. This article discusses the evolution of treatment strategies for KPC-Kp infections over the past decade, guided by clinical evidence and advances in diagnostics.

ANNALS OF MEDICINE (2023)

Add to Collection

Article Infectious Diseases

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections

Victoria Gavaghan et al.

Summary: This case series examines the real-world usage of cefiderocol in treating carbapenem-resistant Gram-negative bacterial infections and its associated clinical outcomes. The study found that cefiderocol remains a viable option for treating these types of infections.

INFECTION (2023)

Add to Collection

Review Infectious Diseases

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales

Keith S. Kaye et al.

Summary: Carbapenem-resistant Enterobacterales (CRE) are a significant public health threat and new antibiotics are needed. The recent approval of ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, plazomicin, eravacycline, and cefiderocol has expanded the options for treating CRE infections. Cefiderocol is a siderophore cephalosporin with potent activity against CRE. It is stable against most carbapenemases, including those detected in CRE. Clinical studies have shown the efficacy and safety of cefiderocol in patients at risk of infection by multidrug-resistant or carbapenem-resistant Gram-negative bacteria. This paper provides a review of cefiderocol's in vitro activity, resistance development, preclinical effectiveness, and clinical experience in the management of CRE infections.

INFECTIOUS DISEASES AND THERAPY (2023)

Add to Collection

Article Immunology

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Jean-Francois Timsit et al.

Summary: The CREDIBLE-CR and APEKS-NP studies showed that cefiderocol treatment is effective against gram-negative bacteria producing metallo-B-lactamases, with favorable rates of clinical cure, microbiological eradication, and all-cause mortality compared to other treatment options.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii

Wentao Ni et al.

Summary: The study found that cefiderocol combined with tigecycline can effectively combat carbapenem-resistant Acinetobacter baumannii, showing synergistic effects regardless of susceptibility or resistance to cefiderocol.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?

Silvia Corcione et al.

Summary: This study evaluated the characteristics and outcomes of patients with Gram-negative infections treated with cefiderocol in combination or monotherapy. The results showed no significant differences in clinical outcomes between combination therapy and monotherapy. Further research is needed to determine if combination therapy with cefiderocol can provide advantages in the prognosis of critically ill patients.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)

Add to Collection

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)

Shabnam Naseer et al.

Summary: Cefiderocol has shown potential efficacy in treating complicated urinary tract infections and other related infections, but may lead to increased mortality in some cases, requiring further research.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol-Based Combination Therapy for Difficult-to-Treat Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Davide Fiore Bavaro et al.

Summary: This study investigated the efficacy of cefiderocol-based combination therapies as rescue treatments for eradicating severe infections caused by multidrug-resistant bacteria. Most patients were immunocompromised or critically ill, and showed good treatment outcomes during the course of therapy, with some deaths attributed to other causes.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Infectious Diseases

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections

Marianna Meschiari et al.

Summary: This study describes the real-life experience of using cefiderocol in XDR and difficult-to-treat resistant Pseudomonas aeruginosa infections without other treatment options available. Clinical cure and microbiological cure rates were 70.6% and 76.5% respectively, with a mortality rate of 35.3%.

JAC-ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Article Infectious Diseases